BioWorld MedTech

Aug. 29, 2012

Aesthetics is going strong while orthopedics struggles

German valve registry reveals real-world TAVI experience

MUNICH, Germany — Minimally invasive aortic valve replacement accounted for 28% of procedures in Germany in 2011, the year following approval of the procedure for reimbursement. Read More

PROTECT trial vindicates DES for long-term benefits

GE Healthcare's Discovery well suited for Hybrid OR

Medtronic reports results from Symplicity HTN-2 trial

Deals roundup: MM to acquire Ascender for undisclosed amount

Court Report: Medtronic expands patent lawsuit against Nuvasive

Med-Tech Notes

Agreements/contracts: PerkinElmer works with Mass Gen on sequencing

HIT roundup: EHNAC set to discuss PHI protection in upcoming webinar

Financings roundup: Nextremity closes $6.6M; opens first preferred round

People in the News

Product Briefs

Medgenics board member Brukardt dies at age 66

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Feb. 14, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 14, 2025

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...